Zobrazeno 1 - 10
of 187
pro vyhledávání: '"Kerry L. Reynolds"'
Autor:
Ayo S. Falade, Kerry L. Reynolds, Leyre Zubiri, Vikram Deshpande, Florian J. Fintelmann, Michael Dougan, Meghan J. Mooradian
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Since the first approval of immune checkpoint inhibitors (ICIs) in 2011, these agents have rapidly become an integral treatment option across tumor types. However, with the increased adoption of ICIs, the incidence of immune-related adverse events (i
Externí odkaz:
https://doaj.org/article/d0ff8795a65a4f67827571a1d51912d6
Autor:
Harish Seethapathy, Sophia Zhao, Ian A. Strohbehn, Meghan Lee, Donald F. Chute, Halla Bates, Gabriel E. Molina, Leyre Zubiri, Shruti Gupta, Shveta Motwani, David E. Leaf, Ryan J. Sullivan, Osama Rahma, Kimberly G. Blumenthal, Alexandra-Chloe Villani, Kerry L. Reynolds, Meghan E. Sise
Publikováno v:
Kidney International Reports, Vol 5, Iss 10, Pp 1700-1705 (2020)
Background: Programmed cell death receptor ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) with a side effect profile that may differ from other classes of ICIs such as those directed against cytotoxic T-lymphocyte−associated pr
Externí odkaz:
https://doaj.org/article/e8904d035ea34b23aca56820cb203d19
Autor:
Michael S. Hughes, Hui Zheng, Leyre Zubiri, Gabriel E. Molina, Steven T. Chen, Meghan J. Mooradian, Ian M. Allen, Kerry L. Reynolds, Michael Dougan
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 4986-4999 (2019)
Abstract Background Immune checkpoint inhibitors (CPIs) have revolutionized oncologic therapy but can lead to immune‐related adverse events (irAEs). Corticosteroids are first‐line treatment with escalation to biologic immunosuppression in refract
Externí odkaz:
https://doaj.org/article/dc34be1618d34608b433f3de2ca9f4c9
Autor:
Andrew J. Piper-Vallillo, MD, Meghan J. Mooradian, MD, Catherine B. Meador, MD, PhD, Beow Y. Yeap, ScD, Jennifer Peterson, BS, Mustafa Sakhi, BS, MS, Andrew Do, BS, Leyre Zubiri, MD, Sara Stevens, NP, Jeanne Vaughn, NP, Kelly Goodwin, NP, Alexander Gavralidis, MD, Henning Willers, MD, Adam Miller, MD, Anna Farago, MD, PhD, Zofia Piotrowska, MD, MHS, Jessica J. Lin, MD, Ibiayi Dagogo-Jack, MD, Inga T. Lennes, MD, MPH, MBA, Lecia V. Sequist, MD, MPH, Jennifer S. Temel, MD, Rebecca S. Heist, MD, Subba Digumarthy, MD, Kerry L. Reynolds, MD, Justin F. Gainor, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100124- (2021)
Introduction: Lung cancer is associated with severe coronavirus disease 2019 (COVID-19) infections. Symptom overlap between COVID-19 and lung cancer may complicate diagnostic evaluation. We aimed to investigate the incidence, symptoms, differential d
Externí odkaz:
https://doaj.org/article/899d24b36a34456388b6d820eedce98b
Autor:
Zsofia D. Drobni, Amna Zafar, Leyre Zubiri, Daniel A. Zlotoff, Raza M. Alvi, Charlotte Lee, Sarah Hartmann, Hannah K. Gilman, Alexandra‐Chloe Villani, Anju Nohria, John D. Groarke, Ryan J. Sullivan, Kerry L. Reynolds, Lili Zhang, Tomas G. Neilan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 23 (2020)
Background Myocarditis attributable to immune checkpoint inhibitor (ICI) therapy is a potentially fatal immune‐related adverse event. Limited data have suggested an association between baseline and on‐treatment absolute lymphocyte count (ALC) and
Externí odkaz:
https://doaj.org/article/c28be87d197a4243bd78d7f461016d21
Autor:
Shijia Zhang, Kimberly Tang, Guihong Wan, Nga Nguyen, Chenyue Lu, Pearl Ugwu-Dike, Neel Raval, Jayhyun Seo, Nora A. Alexander, Ruple Jairath, Jordan Phillipps, Bonnie W. Leung, Kathleen Roster, Wenxin Chen, Leyre Zubiri, Genevieve Boland, Steven T. Chen, Hensin Tsao, Shadmehr Demehri, Nicole R. LeBoeuf, Kerry L. Reynolds, Kun-Hsing Yu, Alexander Gusev, Shawn G. Kwatra, Yevgeniy R. Semenov
Publikováno v:
medRxiv
J Am Acad Dermatol
J Am Acad Dermatol
BackgroundCutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear.ObjectiveTo investigate the association of cirAEs with sur
Publikováno v:
New England Journal of Medicine. 388:165-175
Autor:
Charlotte Lee, Zsofia D. Drobni, Amna Zafar, Carlos A. Gongora, Daniel A. Zlotoff, Raza M. Alvi, Jana Taron, Paula K. Rambarat, Sara Schoenfeld, Ramya C. Mosarla, Vineet K. Raghu, Sarah E. Hartmann, Hannah K. Gilman, Sean P. Murphy, Ryan J. Sullivan, Alexander Faje, Udo Hoffmann, Lili Zhang, Thomas Mayrhofer, Kerry L. Reynolds, Tomas G. Neilan
Publikováno v:
JACC: CardioOncology. 4:660-669
Autor:
Maria S, Asdourian, Nishi, Shah, Ted V, Jacoby, Yevgeniy R, Semenov, Tracey, Otto, Leah L, Thompson, Edward Christopher, Dee, Kerry L, Reynolds, Steven T, Chen
Publikováno v:
Journal of the American Academy of Dermatology. 88:485-487
Autor:
Ted V Jacoby, Maria S Asdourian, Nishi Shah, Tracey S Otto, Leah L Thompson, Kerry L Reynolds, Steven T Chen
Publikováno v:
Clinical and Experimental Dermatology.
Cutaneous immune related adverse events (cirAEs) are a common toxicity due to immune checkpoint inhibitors (ICI) to treat cancer. We provide a case series of 10 patients who presented with low severity cirAEs who had their ICI discontinued against pu